Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy

Press Room

Biotheranostics Announces Contract with Three Rivers Provider Network
Company’s Innovative Genomic-Based Tests for Cancer Now Available to 15 Million Members in the United States
Tennessee Oncology First in Tennessee to Use Test to Determine Risk of Both Early and Late Breast Cancer Recurrence and Likelihood of Benefit from Extended Endocrine Therapy
FOR IMMEDIATE RELEASE…MARCH 12, 2014…SAN DIEGO….Tennessee Oncology, one of the largest physician-owned practices in the United States …
Biotheranostics’ New bioT3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing with Integration of Next Generation Sequencing
Biotheranostics is Now the Industry Leading Provider of Genomic Solutions Across the Continuum of Metastatic Cancer Management
Biotheranostics Signs Collaboration Agreement with Top U.S. Hospital and Reference Laboratory to Offer CancerTYPE ID® Molecular Test for Metastatic Cancer
Use by Mayo Clinic and Mayo Medical Laboratories Expands Availability of Test for Cancer Diagnosis and Tailored Therapy
Biotheranostics’ Breast Cancer IndexSM Molecular Test Identifies Risk for Early and Late Breast Cancer Recurrence, Lancet Oncology Study Finds
Women at low risk for late recurrence can avoid unnecessary treatment; those at high risk can consider further therapy
Biotheranostics Appoints Three Key Executives
Appointments strengthen management team as company expands its commercialization efforts and launches Breast Cancer IndexSM molecular test
Biotheranostics Receives Positive Coverage Decision and In-Network Provider Status from Tufts Health Plan for Its CancerTYPE ID® Molecular Test for Metastatic Cancer
Accurate Diagnosis Is a Foundation for Personalized Medicine for Metastatic Cancer Patients
Studies Show bioTheranostics’ Breast Cancer IndexSM Identifies Breast Cancer Patients at Risk for Early and Late Recurrence, and Predicts Benefit from Extended Endocrine Therapy
Information could allow many women to avoid unnecessary treatment and identify those patients more likely to benefit from continued endocrine therapy
Studies Further Demonstrate Clinical Utility ∓ Cost-Effectiveness of Biotheranostics’ CancerTYPE ID® Molecular Test in Metastatic Cancer
Data released at 2013 ASCO meeting highlight impact of CancerTYPE ID on cancer management
Biotheranostics To Present Data on CancerTYPE ID and Breast Cancer Index at 2013 ASCO Annual Meeting
Data from 11 studies demonstrate the clinical utility and cost-effectiveness of company’s molecular tests for cancer of unknown primary and breast cancer recurrence
Biotheranostics’ Prostate Cancer Index Predicts Risk for Prostate Cancer Recurrence
Study demonstrates clinical validity of new molecular test, which stratifies risk of PSA recurrence and metastasis
bioTheranostics’ CancerTYPE ID® More Accurate than Immunohistochemistry in Diagnosing Metastatic Tumors
Study published in The Journal of Molecular Diagnostics supports the clinical utility of molecular classification in difficult-to-diagnose metastatic cancers